Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.55 EUR | -86.52% |
|
-96.67% | -99.80% |
06-27 | GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650 | MT |
06-27 | GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study | DJ |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 32.65 | 5.462 | 35.83 | 93.05 | 28.84 | 10.56 |
Enterprise Value (EV) 1 | 43.39 | 18.79 | 56.87 | 61.1 | 12.5 | -3.352 |
P/E ratio | -0.13 x | -0.12 x | -1.12 x | -1.48 x | -1.35 x | -1.36 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -2.01 x | -1.64 x | -8.41 x | - | - | - |
EV / FCF | 55.4 x | 80.5 x | -16.6 x | 7.47 x | -1.15 x | 0.71 x |
FCF Yield | 1.81% | 1.24% | -6.02% | 13.4% | -87.3% | 140% |
Price to Book | 2.85 x | -0.3 x | -1.29 x | 4.46 x | 2.47 x | 1.41 x |
Nbr of stocks (in thousands) | 98.5 | 132 | 166 | 1,017 | 1,085 | 1,381 |
Reference price 2 | 331.5 | 41.31 | 216.2 | 91.50 | 26.57 | 7.650 |
Announcement Date | 3/29/19 | 3/27/20 | 4/16/21 | 3/28/22 | 3/30/23 | 3/26/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -21.55 | -11.45 | -6.76 | - | - | - |
EBIT 1 | -21.55 | -11.46 | -6.764 | -57.52 | -21.26 | -13.58 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -259.2 | -38.65 | -28.3 | -58.01 | -20.88 | -7.597 |
Net income 1 | -259.2 | -38.65 | -28.3 | -58.01 | -20.88 | -7.597 |
Net margin | - | - | - | - | - | - |
EPS 2 | -2,631 | -342.6 | -193.6 | -61.81 | -19.66 | -5.637 |
Free Cash Flow 1 | 0.7836 | 0.2334 | -3.422 | 8.175 | -10.91 | -4.701 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/29/19 | 3/27/20 | 4/16/21 | 3/28/22 | 3/30/23 | 3/26/24 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -18.18 | -5.442 | -3.014 | -7.023 | -5.778 | -3.665 | -3.621 | -3.122 | -3.168 | -3.091 |
Operating Margin | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -18.02 | -5.44 | -2.979 | -6.881 | -5.584 | -0.227 | -1.992 | -2.416 | -2.962 | -2.266 |
Net income 1 | -18.02 | -5.44 | -2.979 | -6.881 | -5.584 | -0.227 | -1.992 | -2.416 | -2.962 | -2.266 |
Net margin | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -15.60 | -5.100 | -3.000 | -6.600 | -5.400 | -0.3000 | -1.500 | -1.800 | -5.520 | -1.640 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/28/22 | 5/16/22 | 8/15/22 | 10/31/22 | 3/30/23 | 5/15/23 | 8/7/23 | 11/1/23 | 3/26/24 | 5/15/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 10.7 | 13.3 | 21 | - | - | - |
Net Cash position 1 | - | - | - | 31.9 | 16.3 | 13.9 |
Leverage (Debt/EBITDA) | -0.4986 x | -1.164 x | -3.112 x | - | - | - |
Free Cash Flow 1 | 0.78 | 0.23 | -3.42 | 8.18 | -10.9 | -4.7 |
ROE (net income / shareholders' equity) | -197% | 973% | 116% | 1,542% | -124% | -79.1% |
ROA (Net income/ Total Assets) | -9.63% | -55.5% | -140% | -190% | -54.3% | -55% |
Assets 1 | 2,691 | 69.61 | 20.27 | 30.53 | 38.44 | 13.81 |
Book Value Per Share 2 | 116.0 | -140.0 | -168.0 | 20.50 | 10.80 | 5.410 |
Cash Flow per Share 2 | 0.6000 | 0.2000 | 30.50 | 8.390 | 5.200 | 0.7800 |
Capex 1 | 0.04 | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 3/29/19 | 3/27/20 | 4/16/21 | 3/28/22 | 3/30/23 | 3/26/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+61.53% | 848B | |
+32.95% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+12.27% | 234B | |
+16.12% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |
- Stock Market
- Equities
- GTBP Stock
- GTBP Stock
- Financials GT Biopharma, Inc.